针对性进化和高亲和度ICOS-L变体的模块化集成,用于强大的T细胞介导瘤消除
Ji Yeon Ha1,2, Tae Wook Song3, Petrina Jebamani4
1Department of Biomedical Sciences, Graduate School, Korea University, Seoul, 02841, Republic of Korea.
Journal of biological engineering
|July 11, 2025
概括
改造的ICOS配体 (Y8) 对增强的T细胞激活具有100倍的亲和力. 这种变体在与抗体融合时增强了抗PD-1癌症免疫疗法,改善了瘤细胞溶解.
科学领域:
- 免疫学 免疫学 免疫学
- 蛋白质工程是指蛋白质的工程.
- 癌症免疫疗法癌症免疫疗法
背景情况:
- 推进癌症免疫疗法需要具有精确准和可调节活性的合成免疫调节剂.
- 诱导性T细胞共刺激器 (ICOS) 受体增强T细胞功能,但由于有限的亲和力和形式依赖的活动,在生物发育中面临挑战.
- 优化ICOS连接体 (ICOS-L) 对于开发高亲和度的模块化组件至关重要,用于精确的免疫调节.
研究的目的:
- 为了设计一种高亲和度的ICOS配体变体,以增强T细胞共同刺激.
- 研究工程ICOS-L与抗PD-1疗法的功能协同作用.
- 探索模块化融合格式,以优化生物设计.
主要方法:
- 基于酵母表面显示的定向进化以识别ICOS-L变体.
- 蛋白质工程和结构建模以分析突变 (Q51P,N57H) 以及它们对结合的影响.
- 测量T细胞增殖和细胞因子分泌 (IFN-γ) 的功能性试验.
- 基因融合ICOS-L变体到 pembrolizumab (抗PD-1) 在各种格式.
主要成果:
- 一种ICOS-L变种 (Y8) 具有两个突变 (Q51P,N57H) 显示,与人类ICOS的结合亲和力增加了100倍.
- 结构分析显示,突变增强了刚性,形成了盐桥,重新配置了结合界面.
- Y8诱导了强大的T细胞增殖和IFN-γ分泌.
- Y8与 pembrolizumab的融合增强了T细胞激活和瘤细胞溶解,显示了PD-1阻断和ICOS激动之间的协同作用.
- 轻链结合 (pembrolizumab-L-Y8) 显示出优异的功能输出.
结论:
- Y8是一种高亲和度的ICOS-L变体,具有强大的协同刺激功能.
- Y8可以通过模块化融合加强抗PD-1免疫疗法,提高癌症治疗的疗效.
- 这种工程框架使下一代免疫调节生物药物能够克服耐药性并改善癌症免疫治疗结果.
相关概念视频
T Cell Activation and Clonal Selection
5.2K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
5.2K
Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
Cytotoxic T Cells-mediated Immune Response
2.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.3K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


